使用MRI数据集对阿尔茨海默氏症进行多类分类的新型深度学习
Sumaiya Binte Shahid1, Maleeha Kaikaus1, Md Hasanul Kabir1
1Institute of Information Technology, Jahangirnagar University, Savar, Dhaka, Bangladesh.
Frontiers in bioinformatics
|September 5, 2025
概括
这项研究引入了一个新的深度学习框架,用于精确地从MRI扫描中分类阿尔茨海默病 (AD). 拟议的IncepRes模型具有很高的准确性,有助于早期诊断和AD类别的管理.
科学领域:
- 神经成像和机器学习
- 计算神经科学
- 医疗诊断
背景情况:
- 阿尔茨海默病 (AD) 是神经退行的主要原因,其特点是认知和运动障碍.
- 从MRI扫描中准确分类AD亚型是具有挑战性的,因为重叠的特征.
- 现有的机器学习 (ML) 和深度学习 (DL) 方法难以准确识别多类AD.
研究的目的:
- 开发和评估基于转移学习的特征提取方法,以从MRI扫描中分类AD类别.
- 通过合并Inception和ResNet架构来提议一种新的深度学习模型",IncepRes",以加强AD分类.
- 研究不同转移学习模型 (ResNet152V2,VGG16,InceptionV3,MobileNet) 在AD数据集上的性能.
主要方法:
- 使用四种转移学习模型 (ResNet152V2,VGG16,InceptionV3,MobileNet) 来从MRI扫描中提取特征.
- 利用公开可用的数据集:阿尔茨海默病神经成像计划 (ADNI) 和开放式成像研究系列 (OASIS),以及合并的数据集.
- 开发了一个混合卷积神经网络 (CNN) 模型"IncepRes",集成ResNet152V2和Inception架构,用于多类AD分类.
主要成果:
- 在评估的转移学习方法中,修改后的ResNet152V2表现为优异的特征提取器.
- 拟议的"IncepRes"模型实现了高分类精度:96.96% (ADNI),98.35% (OASIS) 和97.13% (合并数据集).
- 在分类各种阿尔茨海默病类别方面",IncepRes"模型表现优于其他竞争对手的深度学习结构.
结论:
- 拟议的转移学习框架和"IncepRes"模型可以从MRI数据中自动和精确地分类阿尔茨海默病类别.
- 这种进步有助于及时管理和治疗与阿尔茨海默病相关的认知和功能障碍.
- 这项研究强调了深度学习在解决神经退行性疾病诊断中的多类分类挑战方面的有效性.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


